Quince Therapeutics, Inc. Accumulated Other Comprehensive Income
Quince Therapeutics, Inc. (QNCX) had Accumulated Other Comprehensive Income of $4.25 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-14
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $4.25M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $4.61M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $5.75M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $6.29M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $4.25M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $4.61M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $5.75M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $6.29M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $6.16M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $1.96M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$35.00K 10-K · filed 2026-04-10 |
| 2024-09-30 | $3.42M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $1.09M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.82M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $3.05M 10-K · filed 2025-03-24 |
| 2023-09-30 | $516.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $257.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $38.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$289.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$253.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$466.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$506.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$79.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $71.00K 10-Q · filed 2021-10-29 |
| 2021-06-30 | $117.00K 10-Q · filed 2021-08-06 |
| 2021-03-31 | $189.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $313.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $513.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $711.00K 10-Q · filed 2020-08-14 |
| 2020-03-31 | -$37.00K 10-Q · filed 2020-05-12 |
| 2019-12-31 | $60.00K 10-K · filed 2021-03-01 |
| 2019-09-30 | $96.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $80.00K 10-Q · filed 2019-08-09 |
| 2019-03-31 | -$23.00K 10-Q · filed 2019-06-12 |
| 2018-12-31 | -$49.00K 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |